Project Grant R41NS135749

Award Date 6/1/24
Completion Date 11/30/25
Dollars Obligated $986K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This $789,088 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program aims to develop a novel, less invasive tool to ablate the choroid plexus for the treatment of neonatal hydrocephalus. The principal investigator, Childrens Hospital Medical Center, will utilize advanced techniques such as recombinant adeno-associated virus (AAV) vectors,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $903,453 to Vortex Medical Inc. to develop a novel fetal vesico-amniotic shunt for treating fetal lower urinary tract obstruction (LUTO). LUTO is a severe birth defect with a high mortality risk, and current fetal shunt treatments have a high dislodgement rate requiring repeat invasive...
This $307,202 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Wayne State University to optimize shunt catheters for the treatment of hydrocephalus. The award, with an initial term from January 15, 2024 to January 14, 2026, will fund experimental, computational, and analytical studies focused on biomechanics, human injury tolerance, anthropomorphic test device evaluation, and computational modeling...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $666,728 to The Washington University to conduct a comprehensive study of congenital hydrocephalus (CH). The key objectives are to: Establish a large and diverse cohort of primary CH patients, with a focus on recruiting non-European populations, and generate genomic,...
This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), will support the development of an ultrasound-interrogated, implantable sensor for intracranial pressure (ICP) monitoring. The $131,085 award to The Leland Stanford Junior University aims to create a passive, shunt-mountable ICP sensor that can be...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $499,103 to Alleviant Medical, Inc. to advance the commercial readiness of their no-implant interatrial shunt therapy for treating heart failure. The key objectives are to: (1) implement high-volume manufacturing capabilities and production readiness for the ALV1 system, and (2) execute reimbursement and marketing initiatives to establish...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $299,518 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to V-Flow Medical Inc. to develop a novel diagnostic catheter and modular stent system to treat pelvic venous insufficiency (PVI), a primary cause of chronic pelvic pain (CPP) in women. The project will utilize an ovine model to evaluate the safety and efficacy of V-Flow's catheter and stent system in improving clinical outcomes...
This Project Grant award of $1,727,088.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research at Albert Einstein College of Medicine to investigate the restoration of ependymal integrity as a potential therapy for reducing post-hemorrhagic hydrocephalus in preterm infants. The key research objectives are to: 1) Evaluate the impact of...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $171,728 to The Washington University in St. Louis to conduct research investigating the role of cerebrospinal fluid (CSF) flow in regulating the movement of bone marrow-derived myeloid cells to the central nervous system (CNS) borders following spinal cord injury...

LUMBO-VENOUS CSF SHUNT FOR TREATMENT OF COMMUNICATING HYDROCEPHALUS. - PROJECT SUMMARY/ABSTRACT THIS PROPOSAL'S LONG-TERM GOAL IS TO IMPROVE THE CARE OF PATIENTS WITH COMMUNICATING HYDROCEPHALUS, NORMAL PRESSURE HYDROCEPHALUS AND IDIOPATHIC INTRACRANIAL HYPERTENSION. USE OF CSF DIVERSION SYSTEMS SUCH AS LUMBOPERITONEAL SHUNTS, VENTRICULOPERITONEAL SHUNTS AND VENTRICULOATRIAL SHUNTS IS WELL ESTABLISHED, HOWEVER, SUBSTANTIAL LIMITATIONS REMAIN. CURRENT SHUNT SYSTEMS HAVE BEEN IN EXISTENCE FOR DECADES, HOWEVER THEY DO SUFFER FROM MANY LIMITATIONS. SHUNT REVISION RATES DUE TO SHUNT FAILURE ARE EXTREMELY HIGH WITH UP TO ONE-THIRD OF PATIENTS UNDERGOING REVISION SURGERY WITHIN ONE YEAR. INFECTION RATES ARE HIGH AT 20%. OTHER COMMON COMPLICATIONS INCLUDE HEMORRHAGE AND OBSTRUCTION. A FEW GROUPS HAVE PROPOSED THE DEVELOPMENT OF NOVEL MINIMALLY INVASIVE AND EVEN ENDOVASCULARLY DELIVERED CSF DIVERSION SYSTEMS. ONE SUCH SYSTEM INVOLVES THE DELIVERY OF A PUNCTURE NEEDLE TO THE INFERIOR PETROSAL SINUS AT THE SKULL BASE FOLLOWED BY THE DELIVERY OF A SHUNT CATHETER WHICH ALLOWS FOR CSF DIVERSION FROM THE CEREBELLOPONTINE ANGLE TO THE INTERNAL JUGULAR VEIN. EARLY STUDIES WITH THIS DEVICE HAVE BEEN PROMISING, BUT THERE ARE CONCERNS WITH THIS ANATOMICAL APPROACH GIVEN THE PROXIMITY OF THE PUNCTURE NEEDLE TO CRITICAL STRUCTURES INCLUDING THE BASILAR ARTERY AND BRAINSTEM. THROUGH OUR EXPERIENCE IN THE TREATMENT OF A RARE FORM OF SPINAL CSF LEAKS CALLED CSF-VENOUS FISTULAS, OUR GROUP HAS DEVELOPED A VERY LARGE EXPERIENCE IN THE TRANSCATHETER NAVIGATION OF THE SPINAL VENOUS SPACE, PARTICULARLY THE EPIDURAL AND FORAMINAL VEINS AND HAVE REALIZED THE POTENTIAL FEASIBILITY OF TRANSVENOUS TRANSCATHETER DELIVERY OF CATHETERS FROM THE SPINAL VENOUS SPACE TO THE CSF SPACE FOR TREATMENT OF CSF ACCUMULATION DISORDERS. WE HAVE DEMONSTRATED THE ANATOMIC AND TECHNICAL FEASIBILITY IN CADAVER MODELS. IN THIS PHASE I STTR PROGRAM, WE ARE PROPOSING THE DEVELOPMENT OF A NOVEL LUMBO-VENOUS CSF SHUNT FOR TREATMENT OF COMMUNICATING HYDROCEPHALUS. THIS NOVEL CATHETER SYSTEM INCLUDES A NOVEL 6.5FR STEERABLE SHEATH, TRANSVENOUS DURAL PUNCTURE NEEDLE AND AN INNOVATIVE SHUNT CATHETER IMPLANT DESIGN THAT ALLOWS FOR EQUILIBRATION OF CSF PRESSURES WITH THE COMMON ILIAC VEIN AND EASY RETRIEVABILITY. IF SUCCESSFUL, OUR LUMBO-VENOUS CSF SHUNT SYSTEM WILL ENHANCE CARE OF PATIENTS REQUIRING CSF DIVERSION TREATMENTS.

Posted 5/31/24, 12:00 AM